Atom | Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Due Dates: July 14, 2025 (Letter of Intent & Open Date) | August 14, 2025 (Application Due Date) | August 15, 2025 (Expiration)

Funding Amounts: Total program: $2.5M in FY 2026; 3–6 awards; budgets not limited but must reflect project needs; up to 5 years per project.

Summary: Supports research to define how HIV-infected microglia and substance use disorder interact to drive brain region- and cell-type-specific neuropathology.

Key Information: Clinical trials are not allowed; applications relying solely on in vitro models or focused only on alcohol use are not responsive.

Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)

Sign in to see full grant listing